Martin Weiss, deputy editor-in-chief of the investor magazine “Der Aktionär”, takes a close look at the Biogen share (ISIN: US09062X1037, WKN: 789617, ticker symbol: IDP, NASDAQ symbol: BIIB) in a current stock analysis.
Biogen offers a middle that could slow down the progression of Alzheimer’s. That was absolutely honored by the stock market. The stock has been strong over the past few months. It was announced on Friday that the FDA is accelerating the approval process. Biogen and the cooperation partners could therefore earn money more quickly with the drug. Biogen could be one of the big winners this year, according to Martin Weiss, deputy editor-in-chief of the investor magazine “Der Aktionär” on “Der Aktionär TV”. (Analysis from 09.01.2023)
You can read the complete analysis by Martin Weiss, deputy editor-in-chief of the investor magazine “Der Aktionär” on “Der Aktionär TV”. HERE recall.
Please also note information on the disclosure obligation in the event of conflicts of interest within the meaning of Directive 2014/57/EU and corresponding EU regulations under the following link.
Stock exchanges Biogen shares:
Tradegate share price Biogen share:
262,95 EUR +0,11% (09.01.2023, 15:28)
NASDAQ stock price Biogen stock:
278,35 USD -0,32% (09.01.2023, 15:36)
ISIN Biogen share:
WKN Biogen share:
Ticker symbol Biogen share:
NASDAQ symbol Biogen stock:
Course Profile Biogen Inc.:
Biogen Inc. (ISIN: US09062X1037, WKN: 789617, ticker symbol: IDP, NASDAQ symbol: BIIB) is an American biotech group. Biogen Inc. has research interests in multiple sclerosis and oncology, rheumatology and hemophilia. Biogen Inc. was formed in 2003 from the merger of Biogen and Idec Pharmaceuticals. Biogen Inc. is headquartered in Cambridge, Massachusetts, USA. (09.01.2023/ac/a/n)
Disclosure of potential conflicts of interest:
You can view possible conflicts of interest on the site of the creator/source of the analysis.